The Radiopharmaceuticals Market on a global scale was estimated at USD 6.2 Billion in 2024 and is projected to attain USD 19.6 Billion by 2034, with a projected CAGR of 12.7% between 2025 and 2034.
The Radiopharmaceuticals sector involves medications that incorporate radioactive isotopes. This domain has witnessed marked transformation owing to technological breakthroughs and shifting healthcare dynamics.
The market's upward path is fueled by mounting healthcare spending, technological evolution, and the mounting focus on personalized and precision-based approaches in healthcare.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold marked shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and mounting investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radiopharmaceuticals Market Snapshot
Chapter 4. Global Radiopharmaceuticals Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.9. Use/impact of AI on Radiopharmaceuticals Market Industry Trends
4.10. Global Radiopharmaceuticals Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Radiopharmaceuticals Market Segmentation 1: By Radioisotope, Estimates & Trend Analysis
5.1. Market Share by Radioisotope, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Radioisotope:
5.2.1. Technetium 99
5.2.2. Fluorine 18
5.2.3. Iodine 131
5.2.4. Leutetium 177
5.2.5. Yttrium 90
5.2.6. Gallium 67
5.2.7. Gallium 68
5.2.8. Rubidium 82
5.2.9. Iodine 123
5.2.10. Iodine 125
5.2.11. Indium 111
5.2.12. Other Isotopes
Chapter 6. Radiopharmaceuticals Market Segmentation 2: By Indication, Estimates & Trend Analysis
6.1. Market Share by Indication, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
6.2.1. Oncology
6.2.2. Cardiology
6.2.3. Gastroenterology
6.2.4. Neuroendocrinology
6.2.5. Neurology
6.2.6. Nephrology
6.2.7. Other Indications
Chapter 7. Radiopharmaceuticals Market Segmentation 3: By End-User Industry, Estimates & Trend Analysis
7.1. Market Share by End-User Industry, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User Industry:
7.2.1. Hospitals
7.2.2. Medical Imaging Centers
7.2.3. Cancer Research Institute
Chapter 8. Offline Radiopharmaceuticals Market Segmentation 4: By Source, Estimates & Trend Analysis
8.1. Market Share by Source, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Source:
8.2.1. Cyclotrons
8.2.2. Nuclear Reactors
8.2.3. Other Sources
Chapter 9. Radiopharmaceuticals Market Segmentation 5: By Type, Estimates & Trend Analysis
9.1. Market Share by Type, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
9.2.1. Diagnostic
9.2.2. Therapeutic
Chapter 10. Radiopharmaceuticals Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Radiopharmaceuticals Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope, 2021-2034
10.2.3. North America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.2.4. North America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.2.5. North America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
10.2.6. North America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.3. Europe
10.3.1. Europe Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope, 2021-2034
10.3.3. Europe Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.3.4. Europe Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.3.5. Europe Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
10.3.6. Europe Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope, 2021-2034
10.4.3. Asia Pacific Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.4.4. Asia Pacific Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts Source, 2021-2034
10.4.5. Asia Pacific Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.5. Latin America
10.5.1. Latin America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope, 2021-2034
10.5.3. Latin America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.5.4. Latin America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.5.5. Latin America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
10.5.6. Latin America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope, 2021-2034
10.6.3. Middle East & Africa Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.6.4. Middle East & Africa Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.6.5. Middle East & Africa Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
10.6.6. Middle East & Africa Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Novartis AG
11.2.1.1. Business Overview
11.2.1.2. Key Radioisotope/Service Overview
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Curium
11.2.3. Bayer AG
11.2.4. Telix Pharmaceuticals
11.2.5. Lantheus Holdings, Inc.
11.2.6. GE Healthcare
11.2.7. Cardinal Health
11.2.8. Jubilant Pharmova
11.2.9. ITM Isotope Technologies
11.2.10. Eli Lilly (via POINT Biopharma)
11.2.11. AstraZeneca (via Fusion Pharmaceuticals)
11.2.12. PharmaLogic Holdings
11.2.13. Life Molecular Imaging
11.2.14. Bracco Imaging
11.2.15. Siemens Healthineers
11.2.16. Eckert & Ziegler
11.2.17. Advanced Accelerator Applications (AAA)
11.2.18. NorthStar Medical Radioisotopes
11.2.19. Nusano Inc.
11.2.20. Progenics Pharmaceuticals